Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer

PHASE4CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

March 6, 2018

Primary Completion Date

January 9, 2019

Study Completion Date

January 9, 2019

Conditions
Breast Cancer
Interventions
DRUG

Lupin's Pegfilgrastim

Administration of Pegfilgrastim

DRUG

Neulasta®

Administration of Neulasta®

Trial Locations (17)

44026

Clinical Research Department, Bande

125001

Adhar health Institute, Hisar

334003

Acharya Tulsi Regional Cancer Treatment & Research Institute, Bīkaner

380006

Research & Development Department, HCG Cancer Center, Ahmedabad

388325

M S Patel Cancer Centre,, Gokal

390007

Shree Himalaya Cancer Hospital & Research Institute,, Vadodara

391760

Kailash Cancer Hospital & Research Center, Vadodara

395002

Apple Hospital, Surat

Nirmal Hospital, Surat

401107

Bhaktivedanta Hospital & Research Institute, Thāne

411044

Sterling Hospital, Nigdi

440009

Government Medical College & Hospital, Nagpur

500004

Global Clinical Research Services Pvt Ltd., Hyderabad

520002

City Cancer Center, Vijayawada

560068

Sri Venketeshwara Hospital, Dept of Medical oncology, Bengaluru

7000054

Apollo Gleneagles Hospitals, Kolkata

Nasik- 422004

Curie Manavata Cancer Centre, Mumbai

All Listed Sponsors
lead

Lupin Ltd.

INDUSTRY

NCT03511378 - Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer | Biotech Hunter | Biotech Hunter